Calamos Advisors LLC Buys 1,048 Shares of Vertex Pharmaceuticals Incorporated $VRTX

Calamos Advisors LLC grew its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 1.4% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 76,436 shares of the pharmaceutical company’s stock after buying an additional 1,048 shares during the period. Calamos Advisors LLC’s holdings in Vertex Pharmaceuticals were worth $39,962,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. BlackRock Inc. acquired a new position in shares of Vertex Pharmaceuticals during the 2nd quarter valued at about $11,975,849,000. State Street Corp grew its holdings in Vertex Pharmaceuticals by 1.2% during the second quarter. State Street Corp now owns 11,871,459 shares of the pharmaceutical company’s stock valued at $5,896,910,000 after purchasing an additional 141,320 shares during the last quarter. Wellington Management Group LLP raised its position in shares of Vertex Pharmaceuticals by 1.1% in the second quarter. Wellington Management Group LLP now owns 3,247,658 shares of the pharmaceutical company’s stock valued at $1,613,209,000 after purchasing an additional 35,069 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in shares of Vertex Pharmaceuticals by 1.0% in the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,086,683 shares of the pharmaceutical company’s stock valued at $1,533,248,000 after purchasing an additional 29,287 shares during the period. Finally, Bank of America Corp DE acquired a new stake in shares of Vertex Pharmaceuticals in the second quarter worth $1,509,651,000. Institutional investors and hedge funds own 90.96% of the company’s stock.

Wall Street Analyst Weigh In

VRTX has been the topic of several recent analyst reports. UBS Group lifted their target price on shares of Vertex Pharmaceuticals from $615.00 to $640.00 and gave the stock a “buy” rating in a report on Tuesday. Wells Fargo & Company raised their price target on Vertex Pharmaceuticals from $550.00 to $650.00 and gave the company an “overweight” rating in a research report on Tuesday. Stifel Nicolaus raised their price target on Vertex Pharmaceuticals from $500.00 to $563.00 and gave the company a “hold” rating in a research report on Tuesday. The Goldman Sachs Group lifted their price objective on Vertex Pharmaceuticals from $654.00 to $725.00 and gave the stock a “buy” rating in a research note on Tuesday. Finally, Weiss Ratings raised Vertex Pharmaceuticals from a “buy (b-)” rating to a “buy (b)” rating in a research report on Friday, October 16th. One research analyst has rated the stock with a Strong Buy rating, twenty-five have given a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $596.44.

Key Stories Impacting Vertex Pharmaceuticals

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Several analysts reiterated bullish views or raised price targets, including Barclays, Maxim Group, TD Cowen, JPMorgan, Goldman Sachs and Stifel. These updates support the case for further share-price appreciation, though the articles do not provide the revised target figures. Read More. · Read More. · Read More. · Read More.
• Positive Sentiment: A long-term bullish outlook points to Vertex’s strong cystic fibrosis franchise and its gradual diversification into additional businesses as potential drivers of continued growth. A separate report says core business growth remains steady and diversification is beginning to contribute. Read More. · Read More.
• Neutral Sentiment: Vertex said management will participate in three upcoming investor conferences. The appearances may provide updates, but the announcement itself does not disclose new business or financial information. Read More.
• Negative Sentiment: A bearish analysis argues that costs are growing faster than sales and that Vertex may need another major growth driver to justify its valuation. This highlights execution and pipeline risks as investors assess whether diversification can sustain growth. Read More.
• Negative Sentiment: Not all analysts are more optimistic: Morgan Stanley lowered its expectations for the stock, providing a counterpoint to the recent target increases. Read More.

Vertex Pharmaceuticals Price Performance

Shares of Vertex Pharmaceuticals stock traded up $4.59 during midday trading on Friday, hitting $547.09. The company had a trading volume of 1,271,220 shares, compared to its average volume of 1,509,185. Vertex Pharmaceuticals Incorporated has a 1-year low of $406.67 and a 1-year high of $568.67. The business’s 50 day simple moving average is $522.80 and its two-hundred day simple moving average is $481.95. The stock has a market cap of $138.85 billion, a PE ratio of 35.21, a P/E/G ratio of 2.65 and a beta of 0.28.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its earnings results on Monday, November 2nd. The pharmaceutical company reported $4.76 EPS for the quarter, missing the consensus estimate of $4.82 by ($0.06). The company had revenue of $3.44 billion for the quarter, compared to analyst estimates of $3.42 billion. Vertex Pharmaceuticals had a net margin of 30.70% and a return on equity of 22.40%. Vertex Pharmaceuticals’s revenue for the quarter was up 11.8% compared to the same quarter last year. During the same quarter in the previous year, the company earned $4.80 earnings per share. On average, sell-side analysts expect that Vertex Pharmaceuticals Incorporated will post 16.47 EPS for the current fiscal year.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals is a biotechnology company headquartered in Boston, Massachusetts. Founded in 1989, it develops medicines for serious diseases, with a long-standing focus on cystic fibrosis (CF).

Vertex’s CF treatments include medicines that target the underlying protein defect, such as Trikafta/Kaftrio, Alyftrek, Kalydeco, Orkambi and Symdeko/Symkevi. The company also markets Journavx, a non-opioid medicine for acute pain, and partnered with CRISPR Therapeutics to develop Casgevy, a gene-editing treatment for sickle cell disease and transfusion-dependent beta thalassemia.

Vertex serves patients in the United States and international markets, including Europe.